eXIthera Appoints Michael Kurz, Ph.D., to Leadership Team
Dr. Kurz joins eXIthera as the Vice President of Translational Medicine and Medical Affairs Westborough, Mass., June 25, 2019 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications through the inhibition of Factor XIa, today announced the appointment of Michael Kurz, Ph.D., to the company’s leadership team. Dr. Kurz will join […]
eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
Antithrombotic EP-7041 safe and well tolerated; performed in antithrombotic test range associated with clinical efficacy and with fast onset/offset of activity.